Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | P2RY1 | P47900 | 10/20 | 0.63 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.60 |
| ▸ | IDH1 | O75874 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 2/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.56 |
| ▸ | DDX3X | O00571 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22103767 | 0.84 | EPHX2 (0.86) | EPHX2RAB9AMAPTMEN1HTT | |
| SCHEMBL22263059 | 0.83 | MEN1 (0.72) | EPHX2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL11555827 | 0.83 | EPHX2 (1.00) | EPHX2RAB9AMAPTMEN1HTT | |
| SCHEMBL2872598 | 0.83 | EPHX2 (0.69) | EPHX2RAB9AMEN1HTTKMT2A | |
| SCHEMBL17079626 | 0.82 | RAB9A (0.73) | RAB9AMAPTMEN1HTTKMT2A | |
| SCHEMBL14640383 | 0.82 | EPHX2 (0.59) | EPHX2P2RY1STING1IGF1RP2RY14 | |
| SCHEMBL2877898 | 0.82 | EPHX2 (0.68) | EPHX2RAB9ANPC1P2RY1STING1 | |
| SCHEMBL12584976 | 0.82 | EPHX2 (0.83) | EPHX2RAB9AMAPTMEN1HTT | |
| SCHEMBL4106282 | 0.81 | MAPT (0.61) | RAB9AMAPTMEN1HTTKMT2A | |
| SCHEMBL3158123 | 0.80 | P2RY1 (0.69) | EPHX2MAPTHTTP2RY1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| EP-3116852-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | University of Warwick (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | DDX3X, DDX1, DDX5 | EPHX2 1632/4885RAB9A 873/4885MAPT 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.